These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28834396)

  • 21. Levosimendan use in several scenarios of acute heart failure.
    Tavares M; Andrade AC; Mebazaa A
    Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
    Lilleberg J; Ylönen V; Lehtonen L; Toivonen L
    Scand Cardiovasc J; 2004 May; 38(2):80-4. PubMed ID: 15204232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension.
    Jiang R; Zhao QH; Wu WH; Zhang R; Yuan P; Gong SG; He J; Luo CJ; Qiu HL; Wang L; Liu JM
    Clin Respir J; 2018 Apr; 12(4):1518-1525. PubMed ID: 28862394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials.
    Maharaj R; Metaxa V
    Crit Care; 2011 Jun; 15(3):R140. PubMed ID: 21651806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
    Gong B; Li Z; Yat Wong PC
    J Cardiothorac Vasc Anesth; 2015 Dec; 29(6):1415-25. PubMed ID: 26275522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
    Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
    J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
    Landoni G; Biondi-Zoccai G; Greco M; Greco T; Bignami E; Morelli A; Guarracino F; Zangrillo A
    Crit Care Med; 2012 Feb; 40(2):634-46. PubMed ID: 21963578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
    Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
    Int J Cardiol; 2010 Feb; 138(3):281-9. PubMed ID: 18817994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dear levosimendan, the right ventricle will thank you!
    Westphal M; Morelli A; Van Aken H
    Crit Care Med; 2007 Mar; 35(3):952-3. PubMed ID: 17421086
    [No Abstract]   [Full Text] [Related]  

  • 34. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
    Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G
    Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral levosimendan improves filling pressure and systolic function during long-term treatment.
    Jalanko M; Kivikko M; Harjola VP; Nieminen MS; Laine M
    Scand Cardiovasc J; 2011 Apr; 45(2):91-7. PubMed ID: 21348810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
    Palmerini E; Söderberg S; Mondillo S; Favilli R; Lunghetti S
    Acute Card Care; 2015 Mar; 17(1):14-9. PubMed ID: 25806830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
    Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.
    Altenberger J; Parissis JT; Costard-Jaeckle A; Winter A; Ebner C; Karavidas A; Sihorsch K; Avgeropoulou E; Weber T; Dimopoulos L; Ulmer H; Poelzl G
    Eur J Heart Fail; 2014 Aug; 16(8):898-906. PubMed ID: 24920349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.